Neuro-Active Peptides READ MORE

Protagenic Therapeutics, Inc.


Protagenic Therapeutics, Inc. (PTIX) Key Opinion Leader (KOL) PT00114 

First-in-Class Neuropeptides


Our Mission

To develop novel compounds with breakthrough treatment potential for stress-related disorders

Stress-related Disorders


Our Focus

The initial target indications for our lead compound (PT00114) are PTSD and Drug & Alcohol Addiction

Platform Technology


Family of Compounds

Teneurin c-terminal associated peptides (TCAP’s) have the potential to become first-in-class pharmaceutical agents addressing a variety of unmet clinical needs

An innovative, safe and effective treatment for PTSD and Addiction, using neuropeptide hormones to control stress response.